KUALA LUMPUR, Sept 21 (Bernama) -- ImmunoScape, a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR-T-cell therapeutics, announced it has raised US$14 million in new financing. (US$1 = RM4.564)
Existing investor Anzu Partners led the round with participation from new investor Amgen Ventures and Singapore-based global investor EDBI.
“We have made significant strides in our discovery programme and have identified several compelling clinical TCR candidates using our Deep Immunomics platform,” said ImmunoScape Chief Executive Officer, Choon Peng Ng in a statement.
“The new funding will allow us to expedite our development efforts and help us to advance our therapeutic candidates toward the clinic.”
ImmunoScape’s differentiated Deep Immunomics platform utilises the company’s proprietary combinatorial barcoding technology to enable the discovery and indepth characterisation of rare cancer-specific T-cells at high resolution.
ImmunoScape’s platform is able to simultaneously evaluate tens of millions of T-cells in blood samples from hundreds of cancer patients to identify rare clinically relevant T-cell clones.
The corresponding TCRs are then evaluated and prioritised to build a diverse portfolio of TCR-T-cell therapies.
By leveraging computational biology and machine learning, together with high throughput screening and evaluation of T-cell clones, ImmunoScape is able to efficiently identify novel T-cell therapy targets and TCR candidates.
ImmunoScape has extensively validated its computational platform using virus-specific T-cells and is applying the same methods to build an extensive portfolio of cancer-specific TCRs.
More details at https://immunoscape.com/.
-- BERNAMA
No comments:
Post a Comment